Sign In
Buy VIR
$8.66
-0.240 (-2.70%)
At Close: Jul 31, 2026
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced new data from the ongoing Phase 1 clinical trial of VIR-5500, a prostate-specific membrane antigen (PSMA)-targetin
- Astellas and Vir Biotechnology to co-develop and co-commercialize VIR-5500 through a sharing of expenses and revenues - - Astellas to lead commercialization of VIR-5500 in the U.S. with Vir Biotechn
Vir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results
04:05pm, Monday, 09'th Feb 2026
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will host a conference call at 5:30 p.m. ET / 2:30 p.m. PT on Monday, February 23 to provide a corporate u
Vir Biotechnology, Inc. (NASDAQ:VIR) Receives $17.00 Consensus Price Target from Brokerages
01:18am, Monday, 26'th Jan 2026
Shares of Vir Biotechnology, Inc. (NASDAQ: VIR - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the eight brokerages that are covering the company, Marketbeat.co
Vir Biotechnology, Inc. (VIR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
02:25am, Thursday, 15'th Jan 2026
Vir Biotechnology, Inc. (VIR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestones
08:00am, Monday, 12'th Jan 2026
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided key program updates, including new positive data from the ongoing SOLSTICE Phase 2 trial in chronic hepatitis delta
Vir Biotechnology (NASDAQ:VIR) Director Vicki Sato Sells 22,000 Shares of Stock
05:24am, Tuesday, 06'th Jan 2026
Vir Biotechnology, Inc. (NASDAQ: VIR - Get Free Report) Director Vicki Sato sold 22,000 shares of the stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $5.93,
Vir Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference
04:05pm, Monday, 05'th Jan 2026
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the 44th Annual J.P. Morgan
Vir Biotechnology, Inc. (NASDAQ:VIR) Given Average Rating of “Moderate Buy” by Brokerages
05:45am, Monday, 29'th Dec 2025
Vir Biotechnology, Inc. (NASDAQ: VIR - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the eleven analysts that are covering the company, MarketBeat Ratings reports. One r
Analyzing Passage Bio (NASDAQ:PASG) and Vir Biotechnology (NASDAQ:VIR)
02:00am, Saturday, 27'th Dec 2025
Passage Bio (NASDAQ: PASG - Get Free Report) and Vir Biotechnology (NASDAQ: VIR - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two c
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company has granted Norgine Pharma UK Limited, an affiliate of Norgine, a leading European specialty phar
Vir Biotechnology, Inc. (NASDAQ:VIR) Receives $17.30 Consensus Price Target from Brokerages
02:14am, Sunday, 07'th Dec 2025
Vir Biotechnology, Inc. (NASDAQ: VIR - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the eleven brokerages that are presently covering the company, MarketBeat reports.
Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare Conference
04:05pm, Wednesday, 19'th Nov 2025
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the 8
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Week 48 endpoint analysis from the Company's Phase 2 SOLSTICE trial for chronic hepatitis delta (CHD) demonst
Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference
09:00am, Friday, 07'th Nov 2025
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the Jefferies 2025 London Hea
